Pharmacokinetics, Efficacy, and Safety of Encaleret in Pediatric Participants With Autosomal Dominant Hypocalcemia Type 1 (ADH1)
Recruiting now · Phase 2/Phase 3
Conditions studied: Autosomal Dominant Hypocalcemia Type 1 (ADH1)
In brief
The overall objective of this study is to evaluate the pharmacokinetics (PK), efficacy, and safety of encaleret in pediatric participants from birth to 17 years of age with ADH1.
Key facts
- Study ID
- NCT07080385
- Run by
- Calcilytix Therapeutics, Inc., a BridgeBio company
- People needed
- 28
- Starts
- 2026-01-30
- Expected to finish
- 2030-12-01
- Last updated by the study team
- 2026-04-22
Who can join
Age: any, up to 17. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Yale University — New Haven, Connecticut, United States (enrolling)
- Children's National Medical Center — Washington D.C., District of Columbia, United States (enrolling)
- Nemours Children's Health — Jacksonville, Florida, United States (enrolling)
- The Children's Hospital of Philadelphia — Philadelphia, Pennsylvania, United States (enrolling)
- Royal London Hospital — London, United Kingdom (enrolling)
- Royal Manchester Children's Hospital — Manchester, United Kingdom (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.